Anidulafungin: A novel echinocandin

被引:135
作者
Vazquez, Jose A. [1 ]
Sobel, Jack D.
机构
[1] Henry Ford Hosp, Div Infect Dis, Detroit, MI 48202 USA
[2] Wayne State Univ, Sch Med, Detroit, MI USA
关键词
D O I
10.1086/505204
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Until recently, the treatment available for serious fungal infections was composed of amphotericin B and azoles, and each class demonstrated significant limitations. Echinocandins are a new class of drugs that have shown promising results in treating a variety of fungal infections. Of these, anidulafungin is a novel echinocandin that appears to have several advantages over existing antifungals. It is unique because it slowly degrades in humans, undergoing a process of biotransformation rather than being metabolized. It has potent in vitro activity against Aspergillus and Candida species, including those resistant to fluconazole or amphotericin B. Results of several clinical trials indicate that anidulafungin is effective in treating esophageal candidiasis, including azole-refractory disease. The results of a recent study comparing fluconazole versus anidulafungin demonstrated the superiority of anidulafungin in the treatment of candidemia and invasive candidiasis ( IC). Studies evaluating the concomitant use of anidulafungin and either amphotericin B, voriconazole, or cyclosporine did not demonstrate significant drug-drug interactions or adverse events. To date, anidulafungin appears to have an excellent safety profile. On the basis of early clinical experience, it appears that anidulafungin will be a valuable asset in the management of serious and difficult-to-treat fungal infections.
引用
收藏
页码:215 / 222
页数:8
相关论文
共 43 条
[1]   Randomized, double-blind, Multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases [J].
Arathoon, EG ;
Gotuzzo, E ;
Noriega, LM ;
Berman, RS ;
DiNubile, MJ ;
Sable, CA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (02) :451-457
[2]   Mortality and costs of acute renal failure associated with amphotericin B therapy [J].
Bates, DW ;
Su, L ;
Yu, DT ;
Chertow, GM ;
Seger, DL ;
Gomes, DRJ ;
Dasbach, EJ ;
Platt, R .
CLINICAL INFECTIOUS DISEASES, 2001, 32 (05) :686-693
[3]  
BENJAMIN DK, 2004, 44 INT C ANT AG CHEM
[4]   Antifungal susceptibility of South African oral yeast isolates from HIV/AIDS patients and healthy individuals [J].
Blignaut, E ;
Messer, S ;
Hollis, RJ ;
Pfaller, MA .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2002, 44 (02) :169-174
[5]  
BROWN GL, 2000, 40 INT C ANT AG CHEM
[6]   In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients [J].
Chávez, M ;
Bernal, S ;
Valverde, A ;
Gutierrez, MJ ;
Quindós, G ;
Mazuelos, EM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (05) :697-700
[7]   Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B [J].
Cuenca-Estrella, M ;
Mellado, E ;
Díaz-Guerra, TM ;
Monzón, A ;
Rodríguez-Tudela, JL .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (03) :475-477
[8]   Echinocandin antifungal drugs [J].
Denning, DW .
LANCET, 2003, 362 (9390) :1142-1151
[9]   Invasive aspergillosis [J].
Denning, DW .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (04) :781-803
[10]   Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal [J].
Dowell, JA ;
Knebel, W ;
Ludden, T ;
Stogniew, M ;
Krause, D ;
Henkel, T .
JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (06) :590-598